Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (122)
May 31, 2010
-
Maurer's Healthcare Insight (121)
May 3, 2010
-
Maurer's Healthcare Insight (120)
April 12, 2010
-
Maurer's Healthcare Insight (119)
March 1, 2010
-
Maurer's Healthcare Insight (118)
January 4, 2010
-
Maurer's Healthcare Insight (117)
December 14, 2009
-
Maurer's Healthcare Insight (116)
November 30, 2009
-
Maurer's Healthcare Insight (115)
November 16, 2009
-
Maurer's Healthcare Insight (114)
October 26, 2009
-
Maurer's Healthcare Insight (113)
October 5, 2009
-
Maurer's Healthcare Insight (112)
September 14, 2009
-
Maurer's Healthcare Insight (111)
August 24, 2009
-
Maurer's Healthcare Insight (110)
July 27, 2009
-
Maurer's Healthcare Insight (109)
June 22, 2009
-
Maurer's Healthcare Insight (108)
May 18, 2009
-
Maurer's Healthcare Insight (107)
April 27, 2009
-
Maurer's Healthcare Insight (106)
March 30, 2009
-
Maurer's Healthcare Insight (105)
March 2, 2009
-
Maurer's Healthcare Insight (104)
January 26, 2009
-
Maurer's Healthcare Insight (103)
January 5, 2009
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…